Insider at

04

Insider transactions

05
0 buys (P) 0 sells (S) Net: $0 + 25 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

25 other filings hidden
DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
Aug. 29, 2013 PHIO P 1,000 $3.70 $3,700 1,000 Direct · Acquired -100.0% (price as of 2026-10-02)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.

06
DateTickerSecurityUnderlying Exercise priceExpirationSharesA/D
Dec. 11, 2023 XBIO Stock Options Common Stock (10,000) $3.88 Dec. 11, 2033 10,000 Acquired
March 24, 2022 XBIO Stock Options Common Stock (50,000) $1.12 March 24, 2032 50,000 Acquired
March 18, 2021 XBIO Stock Options Common Stock (50,000) $2.60 March 18, 2031 50,000 Acquired
Dec. 4, 2019 XBIO Stock Options Common Stock (90,000) $1.31 Dec. 4, 2029 90,000 Acquired
Feb. 1, 2017 PHIO Stock option (right to buy) Common Stock (2,000) $0.63 Feb. 1, 2027 2,000 Acquired
Feb. 10, 2016 PHIO Stock option (right to buy) Common stock (16,666) $0.29 Feb. 10, 2026 16,666 Acquired
June 2, 2015 PHIO Common stock warrant Common stock (6,000) $0.52 June 2, 2020 6,000 Acquired
June 2, 2015 PHIO Overallotment purchase right Common stock (6,000) $0.46 July 2, 2016 6,000 Acquired
June 1, 2015 PHIO Stock option (right to buy) Common stock (16,666) $0.38 June 1, 2025 16,666 Acquired
June 2, 2014 PHIO Stock Option (right to buy) Common stock (16,666) $2.85 June 2, 2024 16,666 Acquired
April 18, 2013 PHIO Stock Option (right to buy) Common stock (1,000,000) $0.24 April 18, 2023 1,000,000 Acquired
April 18, 2013 PHIO Stock Option (right to buy) Common stock (1,000,000) $0.24 April 18, 2023 1,000,000 Acquired
Dec. 21, 2012 NAGE Employee Stock Options (right to buy) Common Stock (67,500) $1.54 May 10, 2021 67,500 Disposed
Dec. 21, 2012 NAGE Employee Stock Options (right to buy) Common Stock (45,651) $0.94 Sept. 15, 2022 45,651 Acquired
Aug. 28, 2012 NAGE Employee Stock Options (right to buy) Common Stock (67,500) $0.64 Aug. 28, 2022 67,500 Acquired
May 10, 2011 NAGE Employee Stock Options (right to buy) Common Stock (67,500) $1.54 May 10, 2021 67,500 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 11 holdings

07

Securities held when first becoming an insider, per SEC Form 3.

DateTickerSecuritySharesOwnership
Jan. 6, 2017 XBIO Stock Option→ Common Stock (4,849) 4,849 Direct
Jan. 6, 2017 XBIO Stock Option→ Common Stock (4,849) 4,849 Direct
Jan. 6, 2017 XBIO Stock Option→ Common Stock (4,848) 4,848 Direct
Jan. 6, 2017 XBIO Stock Option→ Common Stock (5,051) 5,051 Direct
Jan. 6, 2017 XBIO Stock Option→ Common Stock (5,050) 5,050 Direct
Jan. 6, 2017 XBIO Stock Option→ Common Stock (5,050) 5,050 Direct
Jan. 6, 2017 XBIO Stock Option→ Common Stock (58,334) 58,334 Direct
Jan. 6, 2017 XBIO Stock Option→ Common Stock (58,333) 58,333 Direct
Jan. 6, 2017 XBIO Stock Option→ Common Stock (58,333) 58,333 Direct
Aug. 27, 2008 BCDA Common Stock, par value $0.001 per share 90,960 Direct
Nov. 13, 2007 BCDA Common Stock, par value $0.001 per share 90,960 Direct

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2024 $166,992 · · · · · $387,091 $554,083
2023 $329,175 · · $33,932 $33,411 · $39,298 $435,816
2022 $329,175 · · $49,441 $56,455 · $35,300 $470,371

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.